NCT03169725 - A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants | Biotech Hunter

Enrollment

1,417

Participants

Timeline

Start Date

May 31, 2017

Primary Completion Date

January 18, 2019

Study Completion Date

June 14, 2019

Conditions

Poliomyelitis

Interventions

BIOLOGICAL

Inactivated Poliomyelitis Vaccine (Sabin strain)

Investigational IPV based on Sabin strain (LBVC). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.

BIOLOGICAL

Inactivated Poliomyelitis Vaccine (Salk strain)

Commercialized IPV based on Salk strain (Imovax Polio). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.

Trial Locations (3)

Unknown

Research Institute for Tropical Medicine, Alabang

Mahidol University Faculty of Medicine Siriraj Hospital, Bangkok

Chiang Mai University Maharaj Nakhon Chiang Mai Hospital, Chiang Mai